welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Sucampo Enters Into Exclusive Option and Collaboration Agreement With Cancer Prevention Pharmaceuticals for Development of Late-Stage CPP-1X/Sulindac Combination for Familial Adenomatous Polyposis
Sucampo Pharmaceuticals, Inc., a global biopharmaceutical company, today announced an option and collaboration agreement under which Cancer Prevention Pharmaceuticals, Inc. (CPP) has granted Sucampo the sole option to acquire an exclusive license to commercialize CPP-1X/sulindac combination product in North America. This product is currently in a Phase 3 clinical trial for the treatment of familial adenomatous polyposis (FAP).

expertly curated content related to this topic
-
Henry Ford Health SystemThe Cancer Genetics Program at Henry Fo...
-
Robin K. S. Phillips, MBBS, MS, FRCSRobin K S Phillips is the author of seve...
-
Bonnies Diary Jan 08https://jtvcancersupport.com/embed/29153...
-
Trial In Pediatric Patients With Familial Adenomatous Polyposis (FAP)To test whether celecoxib can be used to...
-
‘Be a Man’ ad Campaign Already Saving Lives‘Be a Man’ ad campaign already savin...
-
Tracy Hull, MDTracy Hull, MD, has been Staff Surgeon i...